Monotherapy with the DNA-alkylating chemotherapeutic temozolomide, an oral metabolite of dacarbazine, showed a partial response (33%) or stable disease (47%) in a total of 80% of patients with SDHB mutations, and thus may be used as a single agent treatment, or alternatively could be considered as a maintenance regime for tumor stabilization subsequent to six–nine cycles of CVD chemotherapy (150 mg/m2 on days 1–5, at 28 day intervals) [149,150]. Here, SDHB is linked to neoplasm.